Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Nuvo Research Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We want to share our innovations with you and learn from your feedback. Help us improve quality and design to make sure your system delivers from day one.
Merck Frosst Canada is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.